Roche To Appeal NICE's Rejection Of Herceptin For HER2-positive Stomach Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
The latest appraisals from NICE include the rejection of Herceptin use in gastric cancer but give positive recommendations to RoActemra and TNF-inhibitors in rheumatoid arthritis.